[New clinical data on erythropoietin therapy of cancer patients with anemia. Summary of the major presentations at the Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, 2005].
Anemia of patients with malignancy might have various reasons. No matter if its background is the underlying tumorous disease or chemo- and/or radiotherapy, it can cause fatigue, malaise, it certainly decreases the patients' quality of life and, furthermore, shortens their survival. Chronic hypoxia caused by anemia promotes tumor progression by several mechanisms e.g. by enhancing angioneogenesis by the production of VEGF. At the same time it decreases the efficacy of chemo- and radiotherapy. Therefore, prevention and/or correction of chemo/radiotherapy-induced anemia is a major goal of modern oncotherapy.
Láng
István
I
Országos Onkológiai Intézet, B Belgyógyászati-Onkológiai és Klinikai Farmakológiai Osztály,Budapestry.
D000740:Anemia / Q000150:complications / Q000188:drug therapy* / Q000209:etiology; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D017024:Chemotherapy, Adjuvant / Q000009:adverse effects; D004921:Erythropoietin / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D000860:Hypoxia / Q000150:complications / Q000209:etiology; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D018714:Radiotherapy, Adjuvant / Q000009:adverse effects; D015996:Survival Rate
D000970:Antineoplastic Agents; D006397:Hematinics; D004921:Erythropoietin